Vosevi is a fixed-dose combination antiviral medicine containing sofosbuvir 400 mg, velpatasvir 100 mg, and voxilaprevir 100 mg. It is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults, particularly in patients who have previously been treated with certain direct-acting antiviral regimens and require a retreatment option.

The three active ingredients target different stages of the hepatitis C virus life cycle. Sofosbuvir inhibits the NS5B RNA polymerase, velpatasvir inhibits the NS5A protein, and voxilaprevir inhibits the NS3/4A protease. Together, these agents work synergistically to prevent viral replication and support viral eradication.

Vosevi is administered as an oral tablet taken once daily with food, with the standard treatment duration typically being 12 weeks, although treatment recommendations may vary based on viral genotype, liver disease status, and previous treatment history.

Clinical studies have demonstrated high sustained virologic response (SVR) rates in patients who were previously difficult to treat, including those with prior exposure to direct-acting antivirals. Successful treatment can help prevent long-term complications of hepatitis C, such as cirrhosis, liver failure, and liver cancer.

Common side effects may include headache, fatigue, diarrhea, nausea, and weakness. Healthcare providers should review liver function, concurrent medications, and potential drug interactions before initiating treatment, as certain medicines may affect the safety or effectiveness of Vosevi.